Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02873962 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 88 | CanariaBio Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT06290193 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01977274 | Predictive Clinical and Biological Parameters in Gynecological Cancer(GC-BIO) | active not recruiting | N/A | 300 | Institut Paoli-CalmettesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05514028 | Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin(OVAmiARN) | active not recruiting | — | 746 | ZIWIGINDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT06969833 | Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma(BCB-OVAIRE) | recruiting | N/A | 371 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00587886 | Estrogen, Diet, Genetics and Endometrial Cancer | active not recruiting | — | 1,315 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05142033 | Avera Cancer Sequencing and Analytics Protocol (ASAP)(ASAP) | recruiting | — | 25,000 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06366490 | Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer | recruiting | Phase 1 | 8 | PhotonPharma, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495384 | Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study | recruiting | N/A | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495397 | Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) | recruiting | N/A | 98 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05427487 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | recruiting | Phase 1 | 70 | ImmVirx Pty LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer(BACON) | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07491081 | EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection | recruiting | N/A | 1,500 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03010124 | Prognostic and Predictive Biomarkers in Ovarian Cancers(OvBIOMark) | recruiting | N/A | 350 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05610735 | Combination Therapy for Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 72 | Sham Sunder KakarOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480785 | TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients | recruiting | N/A | 780 | Zhejiang UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480954 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)(DUAL-OV-CAR-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03519230 | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | active not recruiting | Phase 3 | 224 | BeiGeneINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03842982 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)(CHIPPI) | active not recruiting | Phase 3 | 362 | Centre Oscar LambretOTHER | 2 | Mar 16, 2026 | clinicaltrials |
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | not yet recruiting | Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06483048 | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | recruiting | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07455071 | A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer(YS247) | not yet recruiting | N/A | 9 | Peking University Third HospitalOTHER | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07462468 | A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. | not yet recruiting | Phase 1 | 36 | WestVac Biopharma Co., Ltd.INDUSTRY | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07469709 | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks(PRO-ACTIVE) | recruiting | — | 850 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05763199 | Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy | active not recruiting | Phase 2 | 20 | University of California, DavisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | recruiting | Phase 2 | 148 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03968406 | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | active not recruiting | Phase 3 | 733 | Tesaro, Inc.INDUSTRY | 14 | Mar 10, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07460180 | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer(PROOV) | recruiting | Phase 1 / Phase 2 | 55 | The Netherlands Cancer InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05116189 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | active not recruiting | Phase 3 | 643 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Mar 9, 2026 | clinicaltrials |
| NCT07109414 | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | active not recruiting | Phase 2 / Phase 3 | 380 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | active not recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2026source: clinicaltrials